References
- Fabior® (Tazarotene) Foam 01% [package insert]Research Triangle Park, NCStiefel Laboratories, Inc2012
- SamiNHarperJCTopical retinoidsWolvertonSEComprehensive Dermatologic Drug Therapy2nd edPhiladelphia, PAWB Saunders2007624641
- Del RossoJQPharmacotherapy review: topical tazarotene, a composite review of clinical and research experience with focus on optimal use and safetyJ Am Osteopath Coll Dermatol2004125559
- HuiAMShalitaARTopical retinoidsShalitaARDelRosso JOWebsterGEAcne VulgarisLondonTaylor and Francis Group20118694
- MillikanLEThe rationale for using a topical retinoid for inflammatory acneAm J Clin Dermatol200342758012553848
- ThiboutotDMGollnickHPTreatment considerations for inflammatory acne: clinical evidence for alapalene 0.1% in combination therapiesJ Drugs Dermatol20065878579416989194
- Tazorac® Gel [package insert]Irvine, CAAllergan Inc2011
- BergJEBowmanJPSaenzABCumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studiesCutis201290420621123259209
- HoganDJSaenzABPhototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studiesCutis201290526627123270200
- JarrattMWernerCPAlió SaenzABTazarotene Foam versus Tazarotene Gel: A Randomized Relative Bioavailability Study in Acne VulgarisClin Drug Investig2013334283289
- FeldmanSRWernerCPAlió SaenzABThe Efficacy and Tolerability of Tazarotene Foam, 0.1% in the Treatment of Acne Vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studiesJ Drugs Dermatol201312443844623652892
- SteinGold LJasperSTazarotene foam 0.1% for Acne Vulgaris: analysis of integrated efficacy and safety data by raceProceedings of the Summer Academy Meeting American Academy of Dermatology2012 August 15–19Boston, USA
- Tazorac® cream [package insert]Irvine, CAAllergan Inc2011